REPLIGEN CORP Marketable Securities, Unrealized Gain (Loss)
REPLIGEN CORP (RGEN) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2020-02-26
- REPLIGEN CORP marketable securities, unrealized gain (loss) for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- REPLIGEN CORP marketable securities, unrealized gain (loss) for fiscal 2017 was $5.00K, a 16.67% decline from fiscal 2016.
- REPLIGEN CORP marketable securities, unrealized gain (loss) for fiscal 2016 was $6.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2017-12-31 | $5.00K 10-K · filed 2020-02-26 |
| 2016-12-31 | $6.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |